Skip to main content
. 2010 Nov 19;300(2):L225–L231. doi: 10.1152/ajplung.00264.2010

Fig. 2.

Fig. 2.

Etanercept, a soluble TNF receptor, abolishes doxorubicin-induced diaphragm dysfunction 72 h following injection. A: body weight over 3 days following doxorubicin administration. Diaphragm-specific force (B) and relative force (C) 72 h following injection. Control refers to vehicle for doxorubicin group and vehicle + etanercept group. Data are means ± SE; n = 9 (control), 4 (doxorubicin), 5 (doxorubicin + etanercept). For all panels, P < 0.01 for overall difference by repeated-measures ANOVA; *P < 0.01 (control vs. doxorubicin) or #P < 0.05 (control vs. doxorubicin + etanercept) by Bonferroni test.